Skip to main content

Table 3 Association of tumor morphological features with overall survival

From: Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma

 

Unadjusted models

Adjusted Modelsa

Final Modelb

HR (95%CI)

p-value

HR (95%CI)

p-value

HR (95%CI)

p-value

Pathological features

 STIC

1.38 (0.76–2.50)

0.29

1.35 (0.72–2.54)

0.35

–

–

 TIL

0.92 (0.53–1.59)

0.76

0.84 (0.48–1.47)

0.54

–

–

 Cystic component

0.95 (0.53–1.72)

0.88

1.10 (0.60–2.03)

0.76

–

–

 LVI

3.54 (1.51–8.31)

0.004

2.90 (1.21–6.97)

0.02

3.36 (1.40–8.07)

0.007

Architectural pattern

 Micropapillary

2.10 (1.15–3.82)

0.02

1.61 (0.86–3.04)

0.14

–

–

 Papillary

1.82 (0.91–3.62)

0.09

2.01 (0.99–4.08)

0.05

2.39 (1.17–4.86)

0.02

 Pseudoglandular

0.97 (0.53–1.78)

0.92

0.87 (0.47–1.62)

0.67

–

–

 Solid

0.88 (0.49–1.56)

0.66

0.89 (0.48–1.63)

0.70

–

–

  1. STIC serous tubal intraepithelial carcinoma, TIL tumor-infiltrating lymphocytes, LVI lymphovascular invasion
  2. aModels adjusted for clinical factors: age of diagnosis, stage (I/II vs. III/IV), and response to therapy (sensitive/resistant)
  3. bFinal model contains same  clinical factors as from adjusted model and all significant tumor features
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us